Successful Clinical Study NKP-1339/IT-139

27.10.2011

A Phase I clinical study conducted in the USA has shown the cancer-inhibiting effect and good tolerability of the ruthenium compound NKP1339/IT-139, the most promising project of the research platform "Translational Cancer Therapy Research".